Newron Pharmaceuticals S.p.A. Logo

Newron Pharmaceuticals S.p.A.

Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.

NWRN | SW

Overview

Corporate Details

ISIN(s):
IT0004147952
LEI:
8156002F8C11F80A9740
Country:
Italy
Address:
VIA MEUCCI, 3, 20091 BRESSO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the discovery and development of novel therapies for diseases of the central and peripheral nervous system. The company's research centers on creating new therapeutic classes to address significant unmet medical needs in difficult-to-treat indications, including Parkinson's disease and schizophrenia. Founded in 1999, Newron leverages its proprietary scientific research and clinical development expertise to advance drug candidates from discovery to commercialization, often through strategic partnerships with other pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 07:00
Regulatory News Service
Newron to present new analyses from and updates on its clinical program evaluat…
English 18.0 KB
2025-10-02 02:00
Regulatory News Service
EQS-News: Newron to present new analyses from and updates on its clinical progr…
English 16.4 KB
2025-10-02 02:00
Regulatory News Service
EQS-News: Newron präsentiert neue Analysen und Updates zu seinem klinischen Pro…
German 17.3 KB
2025-09-16 07:00
Earnings Release
Newron veroffentlicht die Ergebnisse des ersten Halbjahres 2025 und gibt ein Up…
German 16.9 KB
2025-09-16 02:00
Earnings Release
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und …
German 15.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron presents H1 2025 results and provides business update
English 24.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und g…
German 28.2 KB
2025-09-05 07:00
Regulatory News Service
Newron to present data and updates on its clinical program evaluating evenamide…
English 19.3 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron to present data and updates on its clinical program evaluating…
English 17.6 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zu…
German 14.3 KB
2025-08-12 07:00
Regulatory News Service
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
English 17.2 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
English 15.8 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
German 18.5 KB
2025-08-11 07:00
Environmental & Social Information
Newron notes the publication of new preclinical research suggesting evenamide a…
English 19.4 KB
2025-08-11 02:00
Regulatory News Service
EQS-News: Newron notes the publication of new preclinical research suggesting e…
English 17.8 KB

Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660

Talk to a Data Expert

Have a question? We'll get back to you promptly.